OncoMatch/Clinical Trials/NCT06932471
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Is NCT06932471 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies MY008211A tablets for paroxysmal nocturnal hemoglobinuria.
Treatment: MY008211A tablets — The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: anti-C5 antibody
Stable regimen of anti-C5 antibody treatment for at least 6 months before treatment
Cannot have received: bone marrow or hematopoietic stem cell transplantation
Previous bone marrow or hematopoietic stem cell transplantation
Cannot have received: splenectomy
Previous splenectomy
Lab requirements
Blood counts
reticulocytes ≥100x10^9/l; platelets ≥30x10^9/l; neutrophils ≥0.5x10^9/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify